The undertreatment of cancer pain remains a significant clinical problem. Of note, large variability exists in pain among individuals. Inadequately controlled pain results in unnecessary suffering and a diminished ability to tolerate primary cancer therapy. New drug formulations and delivery systems are under development, and new approaches are required to individualize pain management.